Adventrx Turns Focus From CoFactor To Vinorelbine, Docetaxel After Phase IIb Failure In CRC

CoFactor/5-FU arm fails to demonstrate significantly improved safety over leucovorin/5-FU in treatment of metastatic colorectal cancer, but method of administration may make a difference, CEO says.